They reported a huge improvment in median overall survival for recurrent / recaclitant Anaplastic Astrocytoma. 1,136 days for this experimental treatment compared to 590 days for the standard Temozolomide. More than double, This is given by convection enhanced delivery.
This drug is a new TGF-Beta antisense drug. It should theoretically work for a wide variety of cancers and is also being studied for use against the COVID-19 virus.
This is a study in mice, so we really do not know how well it would work in people. More research needs to be done.
We are supporting their USA program! This is an experimental treatment for Brain tumors with the H3K27M mutation, such as Diffuse Midline Glioma, and DIPG.
This shows that using Optune during radiation is safe. They were able to complete radiation on all 10 patients without removing the arrays. Early results look promising but too small of a study and too early to tell how well it works.
Interesting new approach.. Works on dogs.. hopefully it will work on people!
These webinars will start this Sunday and we have a great lineup and will be adding more topics! The first event is a must see. There are some issues around the use of chemotherapy and steroids for patients who are exposed to the Covid-19 virus.
This is from our friends at Cancer Commons and xCures.. they are running a virtual trial of the Covid-19 virus. They do not tell you what treatments to do (yet), but will gather information on how the virus affects you, which treatments you decide to do and the outcome. By working together on this, we will get the answers we need quickly. The current research is all over the place - hundreds of small studies that are not centrally gathered and analyzed. This study will cover all of the treatments and quickly let us see what helps the most. This study is IRB approved and listed on clinicaltrials.gov, and is run by a group of experts.
My interest in this project is to see the effects on brain tumor patients. See if they are more or less likely to catch it, based on the chemotherapies and steroids they are taking. And to see how they do. Nobody has studied this yet and we need to know.
There is absolutely no cost to participate. Signing up is easy. Then there is a daily survey where you tell them about any changes in your status or medicines and how you are feeling. You can let your entire family sign up. They want people who are not sick as well as those already sick.
There is a new research collaborative - hopefully this will speed up the research!
Germany finally approved Optune under their national health system.
I thought the USA was slow - Medicare approved it last year - about 4 years after it was approved for newly diagnosed glioblastoma.
It is troubling that there is such a delay between FDA approval and insurance payment approval. The same thing happened with Temodar and Avastin. In the USA, the Medicare approval process should start at the same time as the application to the FDA so the FDA and Medicare approvals come out at the same time.
The more tumor that can be removed safely, the better the patient will do for a longer time. The combination of 5-ala and ultrasound works better than either alone or not using any aide.
This is a difficult study to interpret. There have been many trials of this vaccine. The early trials looked fantastic and this one looks pretty good. However, the largest randomized phase 3 "ACT 4" trial showed no improvement in overall survival. My thoughts are that the vaccine helps some people, with minimal side effects. Not enough to be used by itself but might be part of the ultimate cocktail. Treatments like this would be perfect candidates for the conditional approval pathway we are working on.
Kids with brain tumors have enough problems without having to worry about discrimination. There is no place for this and it should be investigated. I first thought it might be related to insurance or poverty but the article said even if the patient has the same insurance they get treated differently based on skin color. Totally unacceptable.
This article compares using intraoperative MRI to Gleolan (5-ALA) as to the abilty to maximize extent of resection, overall survival and progression free survival.
Intraoperative MRI is just what it sounds like - a machine that is able to do an MRI right in the operating room while you are having a surgery. It is important because when they use navigation systems they use the scans to see where they are on the brain. After they remove most of the tumor, the brain shifts a little, so the pre-op scan is no longer accurate. They can compensate for that by doing another scan while you are in surgery, and it also can see large areas of remaining tumor.
Gleolan is an fda approved dye, taken orally before surgery. During the surgery, when viewed under a special light, any remaining tumor glows and the surgeon can see what needs to be removed.
The study finds that both of these significantly improve survival and all of the other endpoints. It is not clear which one is better, with a hint that the intraoperative MRI is slightly better. I do not see why they can't use both and make it even better. Most hospitals do not have an intraoperative MRI. Any hospital can use Gleolan - a special attachment to an operating microscope is required but the cost is nothing compared to the cost of an MRI machine.
This is a controversial area. Some prior studies on GBM said there was an improvement in progression free survival with Bevacizumab (Avastin) but no improvement in overall survival. This study says there is an improvement with adding Avastin to the standard Temodar, and that benefit persists even if the MGMT is unmethylated. This opens another option for unmethylated MGMT patients. However, I would like to see more data as there are too many conflicting reports.
Interesting read. There was a trial reported last year that adding Lomustine to the standard therapy for newly diagnosed MGMT methylated GBM patients significantly increased the overal survival rate, from 31.4 months to 48.1 months. This article talks about all fo the possible problems with the original article. Not sure what to make of this - let's discuss it in our forum.
They found that most people couldn't stay on the diet for 3 months so the outcome data is meaningless. There are various forms of the keto diet. They tried 2 different forms and both were not patient friendly. Perhaps other versions of the diet would be easier to stay on.
Tamoxifen is an old drug approved for breast cancer. Many years ago, it was tried for glioblastoma. See https://virtualtrials.com/Tam1.cfm That was in the time before Temozolomide was available. Results were promising, but the results for Temozolomide were better so Tamoxifen lost favor.
This article shows a different way it may work, and it may have a role in the ultimate treatment cocktail. By itself, it is obviously not good enough but if this article is correct, it might help other treatments work.
One idea I had is that a possible escape mechanism for Optune is tumor cells getting larger. Tamoxifen might stop the giant cells from forming.
This is a perfect use of our virtual trial system - to track how these additional drugs can help the standard treatments. We need more people to participate. Virtualtrials.com/brain
I had a relative who was diagnosed with a GBM in 1992 and she did well with Tamoxifen for about 5 years, which was amazing back then.
Due to the coronovirus, it probably isn't a great time to put a lot of people close together in a room, so Novocure's next few Open Houses will be online only!